The development of Codebeamer Copilot builds on Volkswagen Group’s adoption of Codebeamer to support software development ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Rating, from 69 to 73.Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The DayThis ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...

PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and ...

I saw Wicked at the Fox in July 2023 with one of my best friends. It was a gift from my mom, my brother and his family for ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the ...

PTC (NASDAQ:PTC – Free Report) had its price objective upped by JPMorgan Chase & Co. from $200.00 to $210.00 in a report ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...